Moderna is reporting that Phase 2/3 trials of its COVID-19 vaccines for babies and young children are concluding that the vaccines seem to be working. The company announced the news via a press release Tuesday (March 23), stating that the shots displayed a “robust neutralizing antibody response” and “a favorable safety profile.”
Moderna’s two children’s doses are for ages six months to 2 years and another for those ages 2 to 6 years. The company also stated it would file for emergency use authorization with the Food and Drug Administration in the coming weeks.
“Given the need for a vaccine against COVID-19 in infants and young children we are working with the U.S. FDA and regulators globally to submit these data as soon as possible,” Moderna CEO Stéphane Bancel said in a statement.
Right now, children under five years old are the only people in the U.S. who are not eligible for a COVID-19 vaccine.
Fellow drugmaker Pfizer has yet to get its COVID-19 vaccine for young children approved by regulators. Pfizer’s CEO recently told CBS that he believes the company’s COVID-19 vaccine for children under 5 to be approved by May.